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METHODOLOGY Open Access
Data sharing in clinical trials – practical
guidance on anonymising trial datasets
Catriona Keerie1* , Christopher Tuck1, Garry Milne1, Sandra Eldridge2, Neil Wright3 and Steff C. Lewis1
Abstract
Background: There is an increasing demand by non-commercial funders that trialists should provide access to trial
data once the primary analysis is completed. This has to take into account concerns about identifying individual
trial participants, and the legal and regulatory requirements.
Methods: Using the good practice guideline laid out by the work funded by the Medical Research Council Hubs
for Trials Methodology Research (MRC HTMR), we anonymised a dataset from a recently completed trial. Using this
example, we present practical guidance on how to anonymise a dataset, and describe rules that could be used on
other trial datasets. We describe how these might differ if the trial was to be made freely available to all, or if the
data could only be accessed with specific permission and data usage agreements in place.
Results: Following the good practice guidelines, we successfully created a controlled access model for trial data
sharing. The data were assessed on a case-by-case basis classifying variables as direct, indirect and superfluous
identifiers with differing methods of anonymisation assigned depending on the type of identifier. A final dataset
was created and checks of the anonymised dataset were applied. Lastly, a procedure for release of the data was
implemented to complete the process.
Conclusions: We have implemented a practical solution to the data anonymisation process resulting in a bespoke
anonymised dataset for a recently completed trial. We have gained useful learnings in terms of efficiency of the
process going forward, the need to balance anonymity with data utilisation and future work that should be
undertaken.
Keywords: Data sharing, Anonymisation, Clinical trial, Controlled access, Direct identifier
Background
There are good reasons why researchers should share
their data with others. Existing research data can be used
to answer questions beyond those planned in the ori-
ginal study, to analyse outcomes that were not included
in the primary analysis, to enable individual participant
data meta-analysis, and to investigate new methodolo-
gies for analysing data. In addition, sharing allows for
transparency as published results can be independently
validated. It is cheaper and more efficient to use existing
data than to collect additional data, and puts fewer pa-
tients at risk. Funders and publishers have updated their
policies to encourage or require data sharing at the
participant level [1], and there is an increasing pressure
to share data.
Other pressures on researchers discourage them from
sharing data. For example, results counter to the spon-
sor/funder expectations or the possibility of future publi-
cations may result in a researcher wishing to keep the
data private. Data ownership could also be considered a
grey area which may prevent the data-sharing mechan-
ism being implemented. Confidentiality of personal in-
formation is covered in the UK by the Common Law
and the Data Protection Act (1998) [2] which follows
the EU Data Protection Directive (1995). Data protection
laws exist in countries outside the EU, with similar pro-
tections. The UK Common Law and Data Protection
Act covers identifiable data on living individuals, and
data that could be identified from other information that
the data controller has or is likely to get. If you have
* Correspondence: catriona.keerie@ed.ac.uk
1Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences
and Informatics, University of Edinburgh, Nine Bioquarter, 9 Little France
Road, Edinburgh EH16 4UX, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keerie et al. Trials  (2018) 19:25 
DOI 10.1186/s13063-017-2382-9
specific consent to share personal data, you can share it
(as specified by the consent). If the participants have
died, they are not subject to the Data Protection Act.
Otherwise, data can only be shared if they are anon-
ymised and the data are not identifiable – and identifia-
bility has to take into account identification that could
be performed through information that the data control-
ler has or is likely to get. Working through these issues
takes time, which may also put researchers off sharing
their data.
The pressure to share data can viewed as both positive
and negative, but should be underpinned by the need to
ensure patient trust at all times [3, 4]. Trying to balance
these pressures leaves researchers caught in the middle.
Guidance on data sharing is available [5–10] and there is
an increasing interest in determining the best method-
ology for carrying out these processes [11, 12]. For re-
searchers, such as ourselves, working in academic trials
units in the UK, the MRC HTMR guidance [5] is par-
ticularly useful. The MRC HTMR guidance says that at
the end of a trial, trialists should prepare an anonymised
dataset ready for sharing, having determined an appro-
priate level of anonymisation. The dataset preparation
should be done by individuals with an understanding of
data management and basic statistics, and there should
be independent quality control. The dataset should be in
a form recognised by a range of software. The pack for
sharing should include supporting documentation in-
cluding the protocol and annotated data collection forms
(including any amendments throughout the study). Al-
though much has been written, there remain gaps in the
detail of exactly what researchers need to do to share
data safely. In particular, the process of anonymisation is
not described in sufficient detail.
It is very hard to completely anonymise data while still
leaving it in an analysable form. Relatively simple facts,
such as age and country of residence, can identify a per-
son if they are exceptionally old – the names, dates of
birth and countries of the world’s oldest living people
are published in Wikipedia [13]. However, it is unlikely
that one of these people will be in a particular research
dataset, but there are an infinite number of other rare
combinations of patient characteristics; and the amount
of information available publicly is ever-growing. As you
remove information from a dataset, you remove inform-
ative detail that is useful in analysis.
This paper describes in detail methods for creating an
anonymised dataset with reference to a recently com-
pleted trial conducted within the Edinburgh Clinical Tri-
als Unit (ECTU).
Methods
The MRC HTMR Good Practice Principles for sharing
individual participant data [5] formed the starting point
in creating an anonymised dataset. The main dataset
used as an example was the TOPPIC trial [14] – a
double-blind, parallel-group randomised trial, investigat-
ing whether mercaptopurine (MP) can prevent or delay
post-operative recurrence of Crohn’s disease. This trial
commenced in 2008 and recruited 240 patients across
29 UK hospitals over a period of 49 months with a 3-
year follow-up.
All decisions and discussion points were recorded
throughout the process and are described in the follow-
ing ‘Results’ section.
Results
The following is a detailed description of the process of
creating an anonymised dataset.
Decide whether to use an open-access or controlled-
access model
Data can be shared using an open-access or a
controlled-access model. In an open-access model, the
dataset is made public, and can be downloaded by any-
one, with no restrictions. In a controlled-access model,
the data are only released if certain conditions are met,
for instance if the requestor can prove that they are a
bona fide researcher with a sensible question to answer,
and if appropriate data-sharing agreements are signed.
Open access is riskier, and a higher level of anonymisa-
tion is necessary to ensure that the data are not consid-
ered personal data and subject to the Data Protection
Act. Unfortunately, as the level of anonymisation in-
creases, the level of data utility decreases, and it may not
be possible to use an open-access model and retain all
the detail to enable someone to repeat the final analysis
exactly. We favour controlled access, as recommended
by the MRC HTMR guidance [5] for several reasons. By
requiring application, researchers have to propose a hy-
pothesis and, therefore, can avoid data dredging. Data
access agreements with recognised institutions and bona
fide researchers can form part of the anonymisation
process and should reduce the risk of any malicious re-
identification. Lastly, a controlled-access model will en-
sure that the original work is credited.
Assemble initial data-sharing pack
The initial data-sharing pack includes the study protocol,
annotated data collection forms, the statistical analysis
plan (SAP), final report and data dictionary, noting any
relevant amendments to these during the study. The an-
notated data collection forms show the variable name and
data table for every data point collected. This information
is also available in tabular form in the data dictionary, but
the data dictionary also details the data type of each vari-
able (e.g. numeric, text). The data dictionary is amended
through the anonymisation process. Although statistical
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analysis programmes can be included in the data-sharing
pack, we have not added them, as they were not prepared
assuming that they would be publicly accessible. However,
it should be noted, that there is value in including statis-
tical analysis programmes in a data-sharing pack. Their in-
clusion can benefit secondary researchers in terms of
learning and can also reduce analysis time following a
data-sharing request.
Identify direct identifiers, indirect identifiers and
superfluous information
The first stage of the data anonymisation process is to
consider every variable and assess whether it is a direct
identifier, an indirect identifier, or superfluous. Hrynasz-
kiewicz [15] lists 28 types of potential participant identi-
fiers, split into direct and indirect identifiers (Table 1).
The direct identifiers are very likely to either immedi-
ately identify a participant or pose a very real risk that
individuals can be identified. Indirect identifiers may
pose a risk in combination with others listed. Problem
variables must either be removed or modified, so that
the risk of identification is diminished. Superfluous data,
such as audit trail data, should be removed.
The original data dictionary is used as the starting point
for documentation of the anonymisation process with each
variable assigned a value. Direct identifiers are given the
values 01–14, indirect identifiers are given the values A–N
and superfluous information is given the value 15 (Table 1).
Assign methods of anonymisation for direct identifiers
Variables coded as direct identifiers were assigned to
two categories:
1. Delete
For the TOPPIC trial, all names, initials, addresses
(including email) relating to patients, relatives and
study personnel were removed from the anonymised
database
2. Modify
Unique identifiers
A unique identifier for each trial participant will always
exist and very often the original unique identifier
assigned can be linked to study sites. Therefore, all
unique identifying numbers (e.g. subject number, pre-
screening identifier) were recoded using random number
generator methodology which ensured reproducibility
and linkage to the original unique identifier (see Add-
itional file 1). The MRC HTMR guidance suggests that
the link between the new code number and the original
unique identifier should be destroyed. For the TOPPIC
trial, the link has been maintained in case of any queries
relating to the anonymised dataset from secondary
researchers.
Other identifier values
Identifier numbers relating to laboratory samples for in-
dividual patients were recoded similarly, while ensuring
that the sample identifier could be linked back to the
correct participant. This also applied to adverse event
identifiers which were required to be linked to the pa-
tient and any associated drug schedule changes resulting
from an adverse event. Bottle codes forming part of the
prescription process were also recoded in this manner.
Dates
All dates relating to individuals (including date of birth)
were classed as direct identifiers. For anonymisation
purposes, date of randomisation was used as a reference
date for each participant, classed as day 0.
Complete dates (i.e. those where a day, month and
year are provided) were modified to be relative to day 0.
For example, a date of randomisation of 15 January 2014
with a date of admission to the trial of 16 January 2014
gives a new study day admission to trial of 1.
Table 1 Aggregated list of potential patient identifiers in
datasets (Hrynaskiewicz [15])
Direct identifiers Indirect identifiers
01. Name A. Place of treatment or health
professional responsible for care
02. Initials B. Sex
03. Address, including full or
partial postal code
C. Rare disease or treatment
04. Telephone or fax numbers or
contact information
D. Sensitive data, such as illicit drug
use or ‘risky behaviour’
05. Electronic mail addresses E. Place of birth
06. Unique identifying numbers F. Socioeconomic data, such as
occupation or place of work, income,
or education
07. Vehicle identifiers G. Household and family
composition
08. Medical device identifiers H. Anthropometry measures
09. Web or internet protocol
addresses
I. Multiple pregnancies
10. Biometric data J. Ethnicity
11. Facial photograph or
comparable image
K. Small denominators – population
size of < 100
12. Audiotapes L. Very small numerators – event
counts of < 3
13. Names of relatives M. Year of birth or age
14. Dates related to an individual
(including date of birth)
N. Verbatim responses or transcripts
Superfluous
02. Superfluous information
(audit trail data, administration
data)
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Partial dates are very often captured, particularly in re-
lation to start and stop dates for concomitant medica-
tions or adverse events. Most commonly the month
and/or year are captured, but not the day, e.g. May 2017,
or just 2009. There are a few solutions to this – the date
could be removed completely, only partial dates could
be removed or a reduced version of the days relative to
randomisation date method could be employed.
For the TOPPIC trial, it was decided that only partial
dates would be removed, i.e. if the day and/or month part
were unknown, days relative to randomisation was not
captured. So, if there were 25 patients with missing day of
medication start, then these 25 dates were removed. There
was an exception to this rule for the primary and second-
ary time-to-event outcomes. Capturing an accurate date is
critical for a time-to-event outcome. There were two in-
stances where secondary endpoint dates were captured as
month and year only. For these occurrences, it was de-
cided that the missing day would be imputed as 15 (i.e.
mid-month) in order that the two patients with a partial
secondary endpoint date would not be excluded from the
secondary outcome analyses. This was in line with how
partial dates were handled in the original statistical ana-
lysis of primary and secondary outcomes.
Assign methods of anonymisation for indirect identifiers
The second pass of the data dictionary involves the in-
direct identifiers, those that may present a risk if present
in combination with others. To decide if these needed
anonymisation a consensus model was used comprising
a trial manager, a statistician and an IT programmer.
Some of the fields (especially those that could potentially
have small event counts), were summarised to help as-
sess the risk.
Variables coded as direct identifiers were assigned to
three categories:
1. Delete
Indirect identifiers which could be considered a rare
disease or treatment (category C) or have a low
event count (category L) were assessed on an
individual basis. Where the disease or treatment
occurred in only one patient, it was decided that this
field should be removed completely. Where the
frequency was greater than two, clinician input was
sought to determine whether the rarity of the
disease or treatment could lead to identification of
individuals.
Verbatim responses or transcripts were removed
since free text can very often reveal personal patient
information. All comments were removed, as were
any descriptions (e.g. adverse event descriptions,
reasons for stopping medication, family history,
physical examination descriptions) and fields relating
to additional information.
Any location-related fields other than study site/
centre were removed, e.g. names of hospitals, loca-
tion of treatments, place of birth.
2. Modify
Study sites/centres were modified in line with the
methods employed for subject number using a
random-number generator approach.
Year of birth or age could be considered to be
indirect identifiers. For TOPPIC, age was categorised
into a small number of groups (i.e. below 16 years,
between 17 and 40 years, above 40 years). This field
was retained in the database as it posed no risk of
patient identification.
3. Leave
Gender was classed as an indirect identifier, but was
retained in the database. This should be assessed on
a trial-by-trial basis as a disproportionate number of
men or women within a trial may lead to patient
identification.
Continuous and ordinal study outcomes were
checked for outliers before making the decision that
identification of patients would not be possible and
that these outcomes could remain in the data
dictionary. These included patient scores (e.g. quality
of life), clinical measurements (e.g. vital signs),
laboratory samples and baseline characteristics (e.g.
height, weight).
Other issues
Sometimes it is necessary to separate out an entire table
of sensitive data with a view to these data being shared
only where a specific request has been made and justifi-
cation given. For TOPPIC, the pregnancy data fell into
this category and no pregnancy-related details were
shared in the anonymised database.
For TOPPIC, a serious adverse event (SAE) was re-
corded which related to the child of a patient born dur-
ing the TOPPIC follow-up period. Several feasible
solutions were presented: (1) anonymise the SAE record,
but link it to the TOPPIC patient (parent), (2) anonym-
ise the SAE record and destroy the link to the TOPPIC
patient and (3) remove the data completely. It was de-
cided that this SAE record should be anonymised, but
the link still retained to the patient with a flag to denote
that this SAE related to the child (solution 1). This way,
individuals would remain unidentified, but this rare
event would be retained within the anonymised data.
Any data/tables relating to trial management were re-
moved from the anonymised database as these were uti-
lised purely for day-to-day running of the trial. These
included monitoring schedules, missing data and track-
ing logs (e.g. blood tests taken), duty rotas, email
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records, non-recruited patient logs and recruitment
targets.
Experience from other anonymised datasets
Other trials going through the same process within
ECTU are BIDS [16] and GaPP [17], both of which have
been published and have provided valuable learnings in
the data anonymisation process, particularly demonstrat-
ing that a standardised solution may not always be the
most appropriate.
The BIDS database captured several time-based fields
(i.e. hours and/or minutes) which could be potentially
identifiable. This aspect of the data does not quite fit
with the list of potential identifiers, as the list only re-
ferred to dates related to an individual, not times. The
potential to create study minutes in the same way as for
study days was discussed, but based on the date and
time of randomisation. A disadvantage to this is that
some data utility could be lost as secondary researchers
would not then know the time of day. In this instance, it
was felt that creating study minutes would not particu-
larly add in terms of anonymisation as dates are already
being modified to a study day. A decision was made to
not modify the hours and minutes component. If this
was an open-access model study minutes may have been
created to make the data less identifiable.
For the GaPP anonymisation process, the decision was
taken to merge some categorical fields in order to pre-
vent patient identification. Adverse events classed as
mild or moderate were combined into one category.
Similarly marital status categories of separated or di-
vorced were combined into a single group.
Other anonymisation complexities to consider are tri-
als researching genetic conditions where a ‘family identi-
fier (ID)’ link within an anonymised environment must
be maintained. The ZiPP [18] trial currently being
undertaken through ECTU is one such study. This fam-
ily ID is an important aspect of the statistical analyses in
terms of the requirement to account for clustering
(within family) effects and is an area we need to give
consideration to for anonymising this data in the future.
Create the final dataset and data dictionary
On completion of the data anonymisation process, the
dataset was exported to delimited text format (i.e.
comma-separated variables (csv)). This can easily be read
into widely available packages such as Microsoft Excel. It
has the advantage that it will continue to be readable
long into the future, whereas other data tables are not
readable as software versions are updated over time.
However, an exception to this would be where values
contain commas (e.g. if there are any text fields).
The folder where these data are stored should be pro-
tected so that they cannot unintentionally be altered.
Data dictionary production can be automated, but for
the TOPPIC trial this was a retrospective and relatively
manual process.
Check the anonymised dataset
1. Is it accurate?
As a check to the anonymised dataset, the ‘gold
standard’ is to independently re-run the analyses
with the modified dataset. This was done for the
TOPPIC trial by the original trial statistician, con-
centrating on the primary and secondary outcomes
only. Minor modifications to the original analysis
programmes were required in order that they would
run correctly with the anonymised data. Corre-
sponding analyses outputs were created in PDF for-
mat and checked against the outputs from the
original statistical report as evidence that the anon-
ymisation process had created a dataset which could
replicate the analyses.
The primary and secondary outcomes were both
time-to-event in nature. As noted earlier, capturing
an accurate date is critical for a time-to-event out-
come and for TOPPIC there were two instances
where secondary endpoint dates were captured as
month and year only. Initially, these partial dates
were set to missing in the anonymisation process ra-
ther than the day being imputed as 15, as had been
the case for the original statistical analyses. This
caused problems with the replication of results for
the secondary outcome as these two records were
excluded from the anonymised analysis re-run, but
had been included in the original analyses. Discus-
sion between the statistician and database program-
mer rectified this minor issue and the partial dates
were imputed in the sharable dataset as mid-month
(i.e. 15) in order that the original statistical analyses
could be replicated.
A cheaper alternative to a complete re-run of the
original analyses would be to check a few key facts
from the main analysis, and use simple automated
checks for the rest. In the programming of the anon-
ymised version of the dataset, it is more likely that
an incorrect variable will be used in place of the
intended one, rather than an individual point in the
dataset being altered. Thus, comparing the difference
between the maximum and minimum values in the
anonymised and original datasets is likely to be suffi-
cient for continuous variables and dates.
2. Is it anonymous?
A motivated intruder test, as suggested by the
Information Commissioners Office [7], can be used
to determine whether the modifications performed
renders the data anonymous in such a way that
Keerie et al. Trials  (2018) 19:25 Page 5 of 8
individual participants are no longer identifiable. In
its simplest form, a person who starts without any
prior knowledge is provided with the dataset and
would attempt to identify individuals from the
dataset. It is assumed that the motivated intruder is
reasonably competent and has access to public
information, but has no specialist skills. This work is
time-consuming and probably practically beyond the
scope of most research groups given their workloads
and budgets.
Release
On completion of the process, a method for release was
devised. The data-sharing pack was created which in-
cluded the anonymised data, the data dictionary, the
SAP, data collection forms and the final protocol. All
items were considered to be freely available with the ex-
ception of the anonymised dataset.
This data-sharing pack was then uploaded to the Uni-
versity of Edinburgh data repository, DataShare [19]
which is based on an open digital repository, DSpace
[20]. This in turn creates a Digital Object Identifier
(DOI) which can be formally referenced.
Once the dataset is uploaded to DataShare, a second-
ary researcher can apply to access the data through the
DataShare system. This sends an email request to a
shared inbox. Once a request is received a simple re-
quest form is sent to the secondary researcher to
complete (see Additional file 2). The application is
reviewed by a committee and, if approved, a data-
sharing agreement is signed between the institutions of
the data owner and the secondary researcher. To release
the data, the request is approved on DataShare and the
anonymised dataset is emailed to the requester.
To aid transparency, all request forms and the deci-
sions made by the committee are published on the
ECTU website.
Discussion
Strengths
Based on MRC guidance, a practical solution has been
presented to create an anonymised dataset which could
be applied across all clinical trials units (CTUs). We
have demonstrated, by means of replication of the TOP-
PIC primary and secondary outcome analyses using an
anonymised dataset, that anonymisation can be balanced
with data utility and practicality. Generic rules can be
created for direct identifiers and decisions on indirect
identifiers can be made on a trial-by-trial basis. The
resulting solution is relatively straightforward and could
easily be implemented either by a statistician or a data-
base programmer.
Through this process, we have been able to create a
generic data-sharing agreement that can be tailored for
individual studies. The data-sharing process has also
been agreed in principle with the TOPPIC trial sponsor.
Limitations
Since this was the first time that we had undertaken a
data-sharing process, it took a relatively long time. Each
dataset (and, in many cases, each data variable within
the dataset) was assessed individually by the team
through joint discussion. With experience, the process
will get quicker, but the more complex the anonymisa-
tion process, the longer it takes and there is a likelihood
of errors arising. As with any bespoke process, there is a
time and cost impact, particularly with regard to the
controlled-access model chosen here. By contrast, an
open-access model is much cheaper. Furthermore, the
controlled-access model can be problematic with respect
to ongoing maintenance if, for instance, no one is
retained at the institution that worked on the original
study, email addresses cease to exist, etc. Long-term
feasibility should be taken into consideration when de-
signing the access model that will be used within an or-
ganisation. Indeed, we have a generic trials unit data-
sharing email address that does not depend on a single
individual from a trial continuing to be employed. Our
processes are being designed to work long after the ori-
ginal trial team ceases to exist.
One final limitation is that the exercise could also be
viewed as moderately subjective, but by working collab-
oratively across disciplines, we have worked around this
by achieving a consensus on all decisions taken.
When should this work be done?
The MRC guidance states that dataset preparation can
either be proactive (prepared in advance) or reactive
(prepared when a request is made). We suggest that a
proactive model is preferred. The process will be quicker
if all this is done at study start-up, rather than at the
end. In addition, it takes a long time to prepare and
check a dataset, and data requestors are likely to be frus-
trated if they have to wait months to receive the data.
As for the specific process of data anonymisation, the
exercise could be split into two separate parts – a first
stage of anonymising direct identifiers, followed by a
second stage of determining indirect identifiers at a sep-
arate point in time. If preferred, all anonymisation can
be performed at the end of the second stage. This was
the case for the TOPPIC trial.
Future work
Future work should concentrate on refining the model
to reduce resource implications in terms of time and
cost. As all CTUs develop their own data-sharing
models, there will be increased interest in creating an ef-
ficient process that is relatively straightforward to follow.
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Work is ongoing to demonstrate the time and cost in-
volved in such an exercise [21].
Going forward, the process should be improved and
refined. Consideration should be given to appropriate
wording for future consent and patient information leaf-
lets within a trials environment and steps are being
taken to address this in line with current recommenda-
tions [3]. There is also a requirement to check copyright
on the data collection forms, particularly questionnaires,
prior to release.
There may be a need to create a formal data-sharing
committee together with a concerted effort to advertise
availability of data. Appropriate documentation should be
embedded in formal processes for all CTUs (e.g. via
Standard Operating Procedures (SOPs)). This future work
will also have resource implications, but should result in a
positive step forward in the data-sharing domain.
Conclusions
We think that the MRC guidance can provide a solution
for CTUs that want or need to share data. We will be
able to create generic rules for direct identifiers, but in-
direct identifiers will probably need a per-trial approach.
As mentioned before, balancing the requirement of
anonymisation with the need for data utility is not al-
ways easy to achieve. The practicality of the anonymisa-
tion process should remain a high priority. Going
forward, we will become more adept at recognising the
types of data that regularly occur within our trials and
how these should be best handled for data sharing, per-
haps via an automated process. However, there will al-
ways be unusual cases within each trial which may mean
full automation is not possible.
Data sharing is a balance of mitigating risk against en-
couraging good use. No system is perfect but it is im-
perative that we develop this aspect of trials reporting in
order to progress towards a fully compliant and robust
end-to-end process.
Additional files
Additional file 1: Methods employed for recoding of unique patient
identifiers. (DOCX 12 kb)
Additional file 2: Data Request Form v1.0 06Jan2017. (DOCX 18 kb)
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